United States (US)

TNF Receptor II recombinant protein

Cat No. GTX65270

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human

Application Note

Potency is determined by its ability to neutralize TNF-alpha mediated growth inhibition of A375 cells, corresponding to a Specific Activity of 1.7x10^7 IU/mg.

Calculated MW

15.0 kDa. ( Note )


Lyophilized powder


1.6 mg mannitol, 0.4 mg sucrose and 48 μg tromethamine per 1 mg protein


Reconstitute in water to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers or store d at 4ºC for 1 week or –20ºC for future use.

Antigen Species


Expression System

CHO cells


Purity was assessed by SDS-PAGE (≥98%) and by HPLC (≥98%).


For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.


TNFR80, TNFR1B, TNFR75, Tumor necrosis factor receptor2, p80 TNFalpha receptor, TNFRSF1B, Tumor necrosis factor receptor type II, p80 TNF-alpha receptor, TNFRII., TNF-R2, TNF-R75, p75, CD120b, TBPII, Tumor necrosis factor receptor 2, p75TNFR, TNFRII, TNF-R-II., TNFR2, TNF-R-II, TNFBR, TNF R2, TNF R75, TNF R II, TNF R II., p80 TNF alpha receptor


Tumor Necrosis Factor Receptor Type II is an inhibitor of TNF and can block TNF bioactivity. Recombinant human TNF-RII produced in CHO is a dimeric, glycosylated, polypeptide chain consisting of the extraCellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of TNFRII contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons.

Research Area

Package List Price ($)
$ 259